Compare BioNano Genomics Inc (BNGO) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs AT&T Inc. — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while AT&T Inc. trades at $24.25 (market cap $167.88B). The key difference: AT&T Inc. is far larger — about 12289.9× BioNano Genomics Inc's market cap, and AT&T Inc. pays a 4.53% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | T | |
|---|---|---|
Market Cap | $13.66M | $167.88B |
Sector | Health | Media |
52-Week High | $4.92 | $29.62 |
52-Week Low | $1.06 | $20.49 |
Enterprise Value | $16.26M | $313.20B |
Dividend Yield | — | 4.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
AT&T (T) trades at $24.19, up 0.46% today, with a bullish technical signal from moving averages but overbought short-term RSI. The company shows strong fundamentals with a P/E of 8.09, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights its focus on fiber expansion and AI integration, while cash flow improved to $15.12B net in 2025.
Outlook is positive with a consensus price target of $27.69, offering 14.5% upside, supported by a 4.8% dividend yield. Risks include competitive pressure from SpaceX's Starlink and high debt levels. Analysts are mixed but lean bullish, with 41% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
